Heteroclitic peptides enhance human immunodeficiency virus-specific CD8+ T cell responses

Vaccine

Volumn 30, Issue 49, 2012, Pages 6997-7004

  Gladney, Krista H ^a   Pohling, Julia ^a   Hollett, Natasha A ^a   Zipperlen, Katrin ^a   Gallant, Maureen E ^a   Grant, Michael D ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

CD8+ T cells; Heteroclitic peptide; HIV; HLA class I; IFN ; IL 2

Indexed keywords

CROSS REACTING ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PEPTIDE VACCINE;

AMINO ACID SUBSTITUTION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV; HIV ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; PEPTIDES;

EID: 84869081289     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.067     Document Type: Article

References (54)

1. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 1994, 68(September (9)):6103-6110.
2. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994, 68(July (7)):4650-4655.
3. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189(March (6)):991-998.
4. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(February (5403)):857-860.
5. Couillin I., Connan F., Culmann-Penciolelli B., Gomard E., Guillet J.G., Choppin J. HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding. Eur. J. Immunol. 1995, 25(March (3)):728-732.
6. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997, 3(February (2)):205-211.
7. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 2000, 192(July (1)):63-75.
8. Chen G., Shankar P., Lange C., Valdez H., Skolnik P.R., Wu L., et al. CD8T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 2001, 98(July (1)):156-164.
9. Lewis D.E., Tang D.S., Adu-Oppong A., Schober W., Rodgers J.R. Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J. Immunol. 1994, 153(July (1)):412-420.
10. Lieberman J., Shankar P., Manjunath N., Andersson J. Dressed to kill? A review of why antiviral CD8T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001, 98(September (6)):1667-1677.
11. Pantaleo G., Koenig S., Baseler M., Lane H.C., Fauci A.S. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25-T cell population. J. Immunol. 1990, 144(March (5)):1696-1704.
12. Trautmann L., Janbazian L., Chomont N., Said E.A., Gimmig S., Bessette B., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 2006, 12(October (10)):1198-1202.
13. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443(September (7109)):350-354.
14. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 2006, 203(October (10)):2281-2292.
15. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., et al. Skewed maturation of memory HIV-specific CD8T lymphocytes. Nature 2001 Mar 1, 410(6824):106-111.
16. Khaitan A., Unutmaz D. Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011, 8(March (1)):4-11.
17. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(June (12)):4781-4789.
18. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 1995, 332(January (4)):201-208.
19. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 2002, 3(November (11)):1061-1068.
20. Zhang J.Y., Zhang Z., Wang X., Fu J.L., Yao J., Jiao Y., et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007, 109(June (11)):4671-4678.
21. Dyall R., Bowne W.B., Weber L.W., LeMaoult J., Szabo P., Moroi Y., et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 1998, 188(November (9)):1553-1561.
22. Zirlik K.M., Zahrieh D., Neuberg D., Gribben J.G. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood 2006, 108(December (12)):3865-3870.
23. Muller D., Pederson K., Murray R., Frelinger J.A. A single amino acid substitution in an MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes. J. Immunol. 1991, 147(August (4)):1392-1397.
24. Solinger A.M., Ultee M.E., Margoliash E., Schwartz R.H. T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J. Exp. Med. 1979, 150(October (4)):830-848.
25. Slansky J.E., Rattis F.M., Boyd L.F., Fahmy T., Jaffee E.M., Schneck J.P., et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000, 13(October (4)):529-538.
26. Tangri S., Ishioka G.Y., Huang X., Sidney J., Southwood S., Fikes J., et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 2001, 194(September (6)):833-846.
27. Horton H., Frank I., Baydo R., Jalbert E., Penn J., Wilson S., et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J. Immunol. 2006, 177(November (10)):7406-7415.
28. Akinsiku O.T., Bansal A., Sabbaj S., Heath S.L., Goepfert P.A. Interleukin-2 production by polyfunctional HIV-1-specific CD8T cells is associated with enhanced viral suppression. J. Acquir. Immune Defic. Syndr. 2011, 58(October (2)):132-140.
29. Grant M.D., Smaill F.M., Singal D.P., Rosenthal K.L. The influence of lymphocyte counts and disease progression on circulating and inducible anti-HIV-1 cytotoxic T-cell activity in HIV-1-infected subjects. AIDS 1992, 6(October (10)):1085-1094.
30. Pohling J., Zipperlen K., Hollett N.A., Gallant M.E., Grant M.D. Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy. BMC Infect. Dis. 2010, 10:129.
31. Mason R.D., Bowmer M.I., Howley C.M., Gallant M., Myers J.C., Grant M.D. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J. Immunol. 2004, 172(June (11)):7212-7219.
32. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003, 77(February (3)):2081-2092.
33. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(March (6)):2709-2714.
34. Sun Y., Schmitz J.E., Buzby A.P., Barker B.R., Rao S.S., Xu L., et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J. Virol. 2006, 80(November (22)):10950-10956.
35. Shan L., Deng K., Shroff N.S., Durand C.M., Rabi S.A., Yang H.C., et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36(March (3)):491-501.
36. Almeida J.R., Sauce D., Price D.A., Papagno L., Shin S.Y., Moris A., et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009, 113(June (25)):6351-6360.
37. Angel J.B., Routy J.P., Tremblay C., Ayers D., Woods R., Singer J., et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011, 25(March (6)):731-739.
38. Garcia F., Lejeune M., Climent N., Gil C., Alcami J., Morente V., et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 2005, 191(May (10)):1680-1685.
39. Levine A.M., Groshen S., Allen J., Munson K.M., Carlo D.J., Daigle A.E., et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 11(April (4)):351-364.
40. MacGregor R.R., Boyer J.D., Ugen K.E., Tebas P., Higgins T.J., Baine Y., et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral blips. Vaccine 2005, 23(March (17-18)):2066-2073.
41. Kran A.M., Sommerfelt M.A., Sorensen B., Nyhus J., Baksaas I., Bruun J.N., et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005, 23(July (31)):4011-4015.
42. Dybul M., Chun T.W., Yoder C., Hidalgo B., Belson M., Hertogs K., et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(December (26)):15161-15166.
43. Doytchinova I.A., Flower D.R. Modeling the peptide-T cell receptor interaction by the comparative molecular similarity indices analysis-soft independent modeling of class analogy technique. J. Med. Chem. 2006, 49(April (7)):2193-2199.
44. Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384(November (6605)):134-141.
45. Mason R.D., Bowmer M.I., Howley C.M., Grant M.D. Cross-reactive cytotoxic T lymphocytes against human immunodeficiency virus type 1 protease and gamma interferon-inducible protein 30. J. Virol. 2005, 79(May (9)):5529-5536.
46. Mason R.D., Grant M.D. A therapy-related point mutation changes the HLA restriction of an HIV-1 Pol epitope from A2 to B57 and enhances its recognition. AIDS 2005, 19(June (9)):981-984.
47. Samri A., Haas G., Duntze J., Bouley J.M., Calvez V., Katlama C., et al. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 2000, 74(October (19)):9306-9312.
48. John M., Moore C.B., James I.R., Mallal S.A. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir. Ther. 2005, 10(4):551-555.
49. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296(May (5572)):1439-1443.
50. Kawashima Y., Pfafferott K., Frater J., Matthews P., Payne R., Addo M., et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009, 458(April (7238)):641-645.
51. Malhotra U., Nolin J., Mullins J.I., McElrath M.J. Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic. Vaccine 2007, 25(January (2)):381-390.
52. Rolland M., Jensen M.A., Nickle D.C., Yan J., Learn G.H., Heath L., et al. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J. Virol. 2007, 81(August (16)):8507-8514.
53. Almeida C.A., Bronke C., Roberts S.G., McKinnon E., Keane N.M., Chopra A., et al. Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J. Immunol. 2011, 187(September (5)):2502-2513.
54. Brumme Z.L., John M., Carlson J.M., Brumme C.J., Chan D., Brockman M.A., et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009, 4(8):e6687.